US2008132709A1PendingUtilityA1
Dat1
Assignee: DEPT OF BIOTECHNOLOGY INDIAPriority: Apr 16, 2004Filed: Apr 16, 2004Published: Jun 5, 2008
Est. expiryApr 16, 2024(expired)· nominal 20-yr term from priority
C07D 277/46A61P 35/00
36
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A synthetic diaminoketothiazole, its process of preparation and its use as a microtubule inhibitor, a probe for tubulin-microtubule system and a cytotoxic agent. Diaminoketothiazole of the formula (I) wherein Ar is 4-OMe-C 6 H 5 , Ar′ is C 6 H 5 .
Claims
exact text as granted — not AI-modified1 - 10 . (canceled)
11 . Diaminoketothiazole of the formula:
wherein Ar is 4-OMe-C 6 H 5 and
Ar′ is C 6 H 5 .
12 . A process for preparing diaminoketothiazole (DAT1), comprising:
reacting aminomethylpolystyrene beads and 1-[N-(arylthiocarbamoyl) amidino]-3,5-dimethylpyrazole to produce N—(N-arylthiocarbamoyl)-N-guanidinomethyl polystyrene (2); reacting said N—(N-arylthiocarbamoyl)-N-guanidinomethyl polystyrene with alphahaloketones in the presence of a base which produces an acyclic S-alkyl intermediate derivative (3); subjecting the acyclic S-alkyl intermediate to the step of cyclisation to obtain the intermediate cyclic thiazoline (4); subjecting the cyclic thiazoline intermediate to the step of eliminative aromatization to produce diaminoketothiazole in a solution; filtering said solution to remove impurities and then isolating 5-aroyl-4-amino-2-arylaminothiazoles from the solution by precipitation.
13 . The process as claimed in claim 12 , wherein said α-haloketones is α-bromoketone.
14 . The process as claimed in claim 13 , wherein said step of precipitation is done by using ice-cold water.
15 . The diaminoketothiazole (DAT1) as claimed in claim 11 , wherein said DAT1 is a microtubule inhibitor and a cytotoxic agent.
16 . The DAT1 as claimed in claim 11 , wherein said DAT1 distorts microtubules in HeLa cells as well as inhibits the in vitro assembly of microtubular proteins.
17 . The DAT1 as claimed in claim 11 , wherein said DAT1 arrests mitosis in diseases where unwanted cell division is involved.
18 . The DAT1 as claimed in claim 11 , wherein said DAT1 is capable of shifting the tubulin-microtubule equilibrium in the cell by inhibiting microtubule polymerization.
19 . The DAT1 as claimed in claim 11 , wherein said DAT1 binds to tubulin with high affinity.
20 . The DAT1 as claimed in claim 19 , wherein said DAT1 binds to tubulin with exhibition of fluorescence.Join the waitlist — get patent alerts
Track US2008132709A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.